Lawton S Cooper

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7039410/publications.pdf

Version: 2024-02-01

17	2,416	15	18
papers	citations	h-index	g-index
18	18	18	3194
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease. New England Journal of Medicine, 2015, 372, 1291-1300.	27.0	1,179
2	Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2017, 318, 713.	7.4	386
3	Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION): Design and rationale. American Heart Journal, 2007, 153, 201-211.	2.7	206
4	Rationale and Design of theÂGUIDE-ITÂStudy. JACC: Heart Failure, 2014, 2, 457-465.	4.1	106
5	PROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial. American Heart Journal, 2014, 167, 796-803.e1.	2.7	104
6	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. JAMA Cardiology, 2020, 5, 757.	6.1	74
7	NT-proBNP Goal Achievement IsÂAssociated With Significant ReverseÂRemodeling and Improved Clinical Outcomes in HFrEF. JACC: Heart Failure, 2019, 7, 158-168.	4.1	65
8	Natriuretic Peptide Response and Outcomes in Chronic HeartÂFailure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 1205-1217.	2.8	54
9	Research Priorities in Atrial Fibrillation Screening. Circulation, 2021, 143, 372-388.	1.6	42
10	Baseline differences in the HF-ACTION trial by sex. American Heart Journal, 2009, 158, S16-S23.	2.7	40
11	Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure. Circulation, 2020, 141, 1915-1926.	1.6	40
12	Clinical factors related to morbidity and mortality in highâ€risk heart failure patients: the GUIDEâ€lT predictive model and risk score. European Journal of Heart Failure, 2019, 21, 770-778.	7.1	36
13	Research Needs and Priorities for Catheter Ablation of Atrial Fibrillation. Circulation, 2020, 141, 482-492.	1.6	25
14	Age-Related Differences in the Noninvasive Evaluation for Possible Coronary Artery Disease. JAMA Cardiology, 2020, 5, 193.	6.1	24
15	Differences in NTâ€proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2021, 10, e019712.	3.7	6
16	The influence of comorbidities on achieving an Nâ€terminal proâ€bâ€type natriuretic peptide target: a secondary analysis of the GUIDEâ€IT trial. ESC Heart Failure, 2021, , .	3.1	3
17	Presenting Symptoms in Patients Undergoing Coronary Artery Disease Evaluation: Association With Noninvasive Test Results and Clinical Outcomes in the PROMISE Trial. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, 101161CIRCOUTCOMES121008298.	2.2	3